![Injectable form of nivolumab vs the intravenous form against kidney cancer – NCI](https://oncodaily.com/pub/uploads/2024/06/Screenshot-2024-06-24-153412-e1719229076328.png)
Photo taken from cancer.gov
Jun 29, 2024, 12:06
Injectable form of nivolumab vs the intravenous form against kidney cancer – NCI
National Cancer Institute (NCI) shared on X:
“In a Clinical Trial, an injectable form of nivolumab (Opdivo) was as effective against kidney cancer as the intravenous form of the drug. Side effects were also similar, and treatment time was shorter.”
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023